| 0 (0%) | 12-08 14:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 54.31  |
1-year : | 63.43 |
| Resists | First : | 46.5 |
Second : | 54.31 |
| Pivot price | 42.85 |
|||
| Supports | First : | 40.77 |
Second : | 37.22 |
| MAs | MA(5) : | 44.17 |
MA(20) : | 42.08 |
| MA(100) : | 38.48 |
MA(250) : | 0 | |
| MACD | MACD : | 1.1 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 85.1 |
D(3) : | 87 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 46.5 | Low : | 26.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XENE ] has closed below upper band by 32.3%. Bollinger Bands are 33.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 45.39 - 45.57 | 45.57 - 45.76 |
| Low: | 44.12 - 44.31 | 44.31 - 44.51 |
| Close: | 44.7 - 45.03 | 45.03 - 45.37 |
Mon, 08 Dec 2025
William Blair Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating - 富途牛牛
Mon, 08 Dec 2025
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Sun, 07 Dec 2025
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Sun, 07 Dec 2025
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
Sun, 07 Dec 2025
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Fri, 05 Dec 2025
Evaluating Xenon Pharmaceuticals (XENE)’s Valuation After Its Recent Share Price Rebound - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 7.176e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 6,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.3818e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 543.7 % |
| Return on Equity (ttm) | -29.5 % |
| Qtrly Rev. Growth | 7.5e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -43.83 |
| EBITDA (p.s.) | -2.57485e+008 |
| Qtrly Earnings Growth | -3.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -252 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.01 |
| Price to Cash Flow | 6.25 |
| Dividend | 0 |
| Forward Dividend | 6.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|